Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin

Xenobiotica

Volumn 31, Issue 10, 2001, Pages 687-699

  Hanioka, N ^a   Ozawa, S ^a   Jinno, H ^a   Ando, M ^a   Saito, Y ^a   Sawada, J ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BILIRUBIN; CHOLIC ACID; GLUCURONOSYLTRANSFERASE; IRINOTECAN; ISOENZYME; PHENOL DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DRUG GLUCURONIDATION; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME POLYMORPHISM; HUMAN; HUMAN CELL; INSECT; LIVER; LIVER MICROSOME; NONHUMAN;

ANIMALS; CAMPTOTHECIN; ENZYME INHIBITORS; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; INSECTS; ISOENZYMES; KINETICS; MICROSOMES, LIVER;

EID: 0034778246     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250110057341     Document Type: Article

References (43)

1. The monkey and human uridine diphosphate-glucuronosyltransferase UGT1A9, expressed in steroid target tissues, are estrogen-conjugating enzymes
2. The UGT1A1*28 allele is relatively rare in a Japanese population
3. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11
4. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome
5. The structure and function of the UDP-glucuronosyltransferase gene family
6. Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation
7. UDP-glucuronosyltransferases
8. Molecular genetic basis of Gilbert's syndrome
9. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus
10. The uridine diphosphate glucuronosyltransferase multigene family: Function and regulation
11. Topoisomerase I inhibitors: Topotecan and irenotecan
12. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
13. Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family
14. Induction of UDP-glucuronosyltransferase by the flavonoids chrysin and quercetin in Caco-2 cells
15. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea
16. Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes
17. High-performance liquid chromatographic assay for glucuronidation activity of 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan (CPT-11), in human liver microsomes
18. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism
19. Genetic predisposition to the metabolism of irinotecan (CPT-11): Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
20. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and a relation to antitumor activity
21. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse
22. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11
23. The specificity of glucuronidation of entacapone and tolcapone by recombinant human udp-glucuronosyltransferases
24. Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine
25. The UDP glycosyltransferase gene superfamily: Recommended nomenclature update based on evolutionary divergence
26. UGT1*1 genotyping in a Canadian Inuit population
27. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome
28. Structural and functional studies of UDP-glucuronosyltransferases
29. Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions
30. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase
31. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
32. TATA-box mutant in the promoter of the uridine diphosphate glucuronosyltransferase gene in Italian patients with Gilbert's syndrome
33. Synthesis and antitumor activity of 20(S)-camptothecin derivatives: Carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin
34. Camptothecin analogues: Studies from the Johns Hopkins Oncology Center
35. Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: Identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue
36. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats
37. Human UDP-glucuronosyltransferases: Metabolism, expression, and disease
38. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts
39. Irinotecan: A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer
40. Glucuronidation in humans: Pharmacogenetic and developmental aspects
41. Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP glycosyltransferase (UGT1A1) gene to phenotypes of Gilbert's syndrome and Crigler-Najjar syndrome type II
42. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts